| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 43 | 2023 | 6550 | 3.680 |
Why?
|
| Severe Combined Immunodeficiency | 10 | 2024 | 107 | 2.080 |
Why?
|
| Transplantation Conditioning | 13 | 2023 | 2238 | 1.570 |
Why?
|
| Granulomatous Disease, Chronic | 5 | 2023 | 79 | 1.530 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 4 | 2020 | 184 | 1.450 |
Why?
|
| Alemtuzumab | 3 | 2021 | 198 | 1.300 |
Why?
|
| Thrombotic Microangiopathies | 2 | 2019 | 70 | 1.270 |
Why?
|
| Graft vs Host Disease | 18 | 2023 | 2638 | 1.140 |
Why?
|
| Immunologic Deficiency Syndromes | 4 | 2021 | 238 | 0.940 |
Why?
|
| Cord Blood Stem Cell Transplantation | 3 | 2023 | 362 | 0.910 |
Why?
|
| Wiskott-Aldrich Syndrome | 2 | 2020 | 24 | 0.820 |
Why?
|
| Agammaglobulinemia | 2 | 2022 | 46 | 0.810 |
Why?
|
| T-Lymphocytes | 14 | 2024 | 3869 | 0.740 |
Why?
|
| Complement C3b | 1 | 2019 | 10 | 0.730 |
Why?
|
| Thiotepa | 1 | 2020 | 118 | 0.730 |
Why?
|
| Complement Factor B | 1 | 2019 | 13 | 0.720 |
Why?
|
| Complement Pathway, Alternative | 1 | 2019 | 20 | 0.710 |
Why?
|
| Bone Marrow Transplantation | 5 | 2017 | 1581 | 0.670 |
Why?
|
| Child, Preschool | 28 | 2023 | 16273 | 0.670 |
Why?
|
| Unrelated Donors | 6 | 2021 | 304 | 0.660 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2023 | 180 | 0.660 |
Why?
|
| Autoimmune Diseases | 2 | 2018 | 402 | 0.630 |
Why?
|
| BK Virus | 2 | 2018 | 123 | 0.620 |
Why?
|
| Organophosphonates | 1 | 2018 | 64 | 0.610 |
Why?
|
| Graft vs Host Reaction | 1 | 2017 | 59 | 0.610 |
Why?
|
| Plasma Exchange | 1 | 2018 | 117 | 0.600 |
Why?
|
| Cytosine | 1 | 2018 | 141 | 0.590 |
Why?
|
| Infant | 25 | 2023 | 13310 | 0.580 |
Why?
|
| Child | 35 | 2023 | 29154 | 0.580 |
Why?
|
| Cystitis | 1 | 2018 | 107 | 0.580 |
Why?
|
| Polyomavirus Infections | 1 | 2018 | 139 | 0.580 |
Why?
|
| Tumor Virus Infections | 1 | 2018 | 224 | 0.560 |
Why?
|
| Infection Control | 1 | 2018 | 270 | 0.560 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2020 | 588 | 0.560 |
Why?
|
| Transplantation, Homologous | 13 | 2023 | 2843 | 0.530 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 602 | 0.510 |
Why?
|
| Tissue Donors | 4 | 2019 | 769 | 0.480 |
Why?
|
| Adolescent | 27 | 2022 | 31252 | 0.430 |
Why?
|
| Antiviral Agents | 2 | 2023 | 1230 | 0.410 |
Why?
|
| Virus Diseases | 4 | 2023 | 398 | 0.390 |
Why?
|
| Stem Cell Transplantation | 2 | 2017 | 1360 | 0.380 |
Why?
|
| Neonatal Screening | 4 | 2024 | 165 | 0.360 |
Why?
|
| DNA-Binding Proteins | 1 | 2023 | 4821 | 0.350 |
Why?
|
| Biomarkers | 2 | 2019 | 5047 | 0.350 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 787 | 0.350 |
Why?
|
| Immunotherapy, Adoptive | 6 | 2017 | 1763 | 0.350 |
Why?
|
| Infant, Newborn | 14 | 2024 | 8223 | 0.340 |
Why?
|
| Caspase 9 | 3 | 2015 | 189 | 0.340 |
Why?
|
| Immune Reconstitution | 2 | 2018 | 22 | 0.320 |
Why?
|
| Humans | 58 | 2024 | 261506 | 0.310 |
Why?
|
| Allografts | 3 | 2018 | 650 | 0.310 |
Why?
|
| Bone Marrow Cells | 3 | 2013 | 943 | 0.300 |
Why?
|
| Gangliosides | 1 | 2007 | 95 | 0.280 |
Why?
|
| Cytomegalovirus | 3 | 2019 | 482 | 0.270 |
Why?
|
| DNA Viruses | 2 | 2017 | 48 | 0.260 |
Why?
|
| Male | 32 | 2022 | 123000 | 0.250 |
Why?
|
| Adoptive Transfer | 2 | 2019 | 446 | 0.240 |
Why?
|
| Leukemia | 4 | 2022 | 1635 | 0.230 |
Why?
|
| Retrospective Studies | 17 | 2023 | 37905 | 0.220 |
Why?
|
| Female | 29 | 2020 | 141928 | 0.210 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 14889 | 0.210 |
Why?
|
| Mycobacterium bovis | 1 | 2022 | 67 | 0.200 |
Why?
|
| Lymphopenia | 1 | 2024 | 199 | 0.200 |
Why?
|
| Early Diagnosis | 1 | 2023 | 298 | 0.200 |
Why?
|
| Thymus Gland | 1 | 2023 | 294 | 0.200 |
Why?
|
| Burkitt Lymphoma | 1 | 2023 | 335 | 0.190 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2023 | 489 | 0.190 |
Why?
|
| Wiskott-Aldrich Syndrome Protein | 1 | 2020 | 10 | 0.190 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 482 | 0.190 |
Why?
|
| Interferon Type I | 1 | 2021 | 250 | 0.190 |
Why?
|
| Cytomegalovirus Infections | 3 | 2019 | 462 | 0.190 |
Why?
|
| Transplant Recipients | 2 | 2020 | 324 | 0.180 |
Why?
|
| Acute Disease | 4 | 2022 | 2422 | 0.180 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 246 | 0.180 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2023 | 406 | 0.180 |
Why?
|
| Cost of Illness | 1 | 2023 | 498 | 0.170 |
Why?
|
| Complement Activation | 1 | 2019 | 94 | 0.170 |
Why?
|
| Biological Specimen Banks | 1 | 2019 | 76 | 0.170 |
Why?
|
| Busulfan | 1 | 2023 | 764 | 0.170 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2011 | 216 | 0.170 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2018 | 31 | 0.170 |
Why?
|
| Young Adult | 12 | 2022 | 21445 | 0.170 |
Why?
|
| Osteoblasts | 2 | 2013 | 370 | 0.160 |
Why?
|
| Immunity, Cellular | 2 | 2017 | 419 | 0.160 |
Why?
|
| Chimerism | 1 | 2018 | 63 | 0.160 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2018 | 35 | 0.160 |
Why?
|
| Antigens, Viral | 2 | 2017 | 471 | 0.160 |
Why?
|
| Adult | 14 | 2023 | 77950 | 0.160 |
Why?
|
| Parainfluenza Virus 3, Human | 1 | 2017 | 15 | 0.160 |
Why?
|
| Bone Marrow Diseases | 1 | 2018 | 177 | 0.150 |
Why?
|
| Respirovirus Infections | 1 | 2017 | 35 | 0.150 |
Why?
|
| Anemia, Sickle Cell | 1 | 2021 | 339 | 0.150 |
Why?
|
| Administration, Intravesical | 1 | 2018 | 162 | 0.150 |
Why?
|
| Pancytopenia | 1 | 2018 | 120 | 0.150 |
Why?
|
| DNA Virus Infections | 1 | 2017 | 29 | 0.150 |
Why?
|
| Breast Feeding | 1 | 2019 | 239 | 0.150 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2017 | 709 | 0.150 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2017 | 69 | 0.150 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 2796 | 0.150 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2017 | 47 | 0.150 |
Why?
|
| Anemia, Aplastic | 1 | 2018 | 214 | 0.150 |
Why?
|
| Immune System Diseases | 1 | 2017 | 65 | 0.150 |
Why?
|
| Metabolic Diseases | 1 | 2018 | 130 | 0.150 |
Why?
|
| Metapneumovirus | 1 | 2017 | 58 | 0.150 |
Why?
|
| Myeloablative Agonists | 2 | 2020 | 384 | 0.150 |
Why?
|
| Paramyxoviridae Infections | 1 | 2017 | 86 | 0.150 |
Why?
|
| Recurrence | 6 | 2023 | 4758 | 0.140 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 2 | 2018 | 387 | 0.140 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 3001 | 0.140 |
Why?
|
| Genes, Transgenic, Suicide | 2 | 2015 | 69 | 0.130 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 673 | 0.130 |
Why?
|
| Tuberculosis | 1 | 2022 | 548 | 0.130 |
Why?
|
| Prospective Studies | 4 | 2023 | 12873 | 0.130 |
Why?
|
| Cytokines | 2 | 2021 | 2809 | 0.130 |
Why?
|
| Phosphoglucomutase | 1 | 2014 | 9 | 0.130 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 1021 | 0.120 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1945 | 0.120 |
Why?
|
| Herpesvirus 4, Human | 4 | 2023 | 966 | 0.120 |
Why?
|
| Bone Diseases, Developmental | 1 | 2014 | 70 | 0.120 |
Why?
|
| Congenital Disorders of Glycosylation | 1 | 2014 | 37 | 0.120 |
Why?
|
| Diarrhea | 1 | 2017 | 686 | 0.120 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2013 | 34 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2018 | 1033 | 0.110 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2019 | 1039 | 0.110 |
Why?
|
| Hodgkin Disease | 1 | 2022 | 1429 | 0.110 |
Why?
|
| Forkhead Transcription Factors | 1 | 2017 | 778 | 0.110 |
Why?
|
| Viruses | 1 | 2014 | 159 | 0.110 |
Why?
|
| Survival Rate | 4 | 2020 | 12221 | 0.110 |
Why?
|
| Adenoviridae Infections | 1 | 2013 | 125 | 0.110 |
Why?
|
| Epitopes | 1 | 2015 | 685 | 0.110 |
Why?
|
| Incidence | 2 | 2023 | 5673 | 0.110 |
Why?
|
| Sibling Relations | 1 | 2011 | 13 | 0.100 |
Why?
|
| Transgenes | 1 | 2014 | 557 | 0.100 |
Why?
|
| Herpesviridae Infections | 1 | 2013 | 175 | 0.100 |
Why?
|
| Exome | 1 | 2017 | 1239 | 0.100 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2011 | 87 | 0.100 |
Why?
|
| Skin Diseases | 1 | 2014 | 349 | 0.100 |
Why?
|
| Pyridines | 1 | 2018 | 1244 | 0.100 |
Why?
|
| Mutation | 4 | 2022 | 15179 | 0.090 |
Why?
|
| Educational Status | 1 | 2011 | 397 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2017 | 830 | 0.090 |
Why?
|
| Case-Control Studies | 1 | 2019 | 6100 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2018 | 1589 | 0.090 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 1946 | 0.090 |
Why?
|
| Genome, Human | 1 | 2018 | 1869 | 0.090 |
Why?
|
| Organic Chemicals | 3 | 2015 | 113 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2018 | 1471 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 2483 | 0.090 |
Why?
|
| Treatment Outcome | 9 | 2020 | 32848 | 0.090 |
Why?
|
| Killer Cells, Natural | 1 | 2014 | 904 | 0.080 |
Why?
|
| Age Factors | 1 | 2018 | 5377 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 2291 | 0.080 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 10001 | 0.080 |
Why?
|
| Activities of Daily Living | 1 | 2011 | 552 | 0.080 |
Why?
|
| Flow Cytometry | 3 | 2015 | 3033 | 0.080 |
Why?
|
| Lung | 1 | 2019 | 3151 | 0.080 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2013 | 1016 | 0.080 |
Why?
|
| Genotype | 3 | 2023 | 4109 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 4744 | 0.080 |
Why?
|
| Prognosis | 3 | 2020 | 21713 | 0.080 |
Why?
|
| N-Acetylgalactosaminyltransferases | 1 | 2007 | 12 | 0.080 |
Why?
|
| Antigens, Surface | 1 | 2007 | 295 | 0.070 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 980 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 1 | 2018 | 4975 | 0.070 |
Why?
|
| Graft Survival | 1 | 2008 | 1062 | 0.060 |
Why?
|
| Risk Factors | 2 | 2017 | 17523 | 0.060 |
Why?
|
| Transplantation, Autologous | 2 | 2022 | 1914 | 0.060 |
Why?
|
| Hematologic Neoplasms | 1 | 2015 | 1870 | 0.060 |
Why?
|
| Aspergillus fumigatus | 2 | 2014 | 135 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2013 | 5637 | 0.060 |
Why?
|
| Stromal Cells | 1 | 2007 | 825 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 4757 | 0.050 |
Why?
|
| Adenosine Deaminase | 1 | 2022 | 94 | 0.050 |
Why?
|
| Canada | 1 | 2023 | 429 | 0.050 |
Why?
|
| Carmustine | 1 | 2022 | 214 | 0.050 |
Why?
|
| Pedigree | 2 | 2017 | 1890 | 0.050 |
Why?
|
| Adipose Tissue | 1 | 2007 | 769 | 0.050 |
Why?
|
| I-kappa B Kinase | 1 | 2022 | 250 | 0.050 |
Why?
|
| Monitoring, Immunologic | 1 | 2020 | 47 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2007 | 1682 | 0.050 |
Why?
|
| Tissue Banks | 1 | 2019 | 55 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2022 | 671 | 0.040 |
Why?
|
| BCG Vaccine | 1 | 2022 | 399 | 0.040 |
Why?
|
| Melphalan | 1 | 2022 | 834 | 0.040 |
Why?
|
| Fetal Blood | 1 | 2021 | 482 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 485 | 0.040 |
Why?
|
| Quality of Life | 1 | 2011 | 4532 | 0.040 |
Why?
|
| Granzymes | 1 | 2017 | 91 | 0.040 |
Why?
|
| Heredity | 1 | 2017 | 29 | 0.040 |
Why?
|
| Multifactorial Inheritance | 1 | 2018 | 148 | 0.040 |
Why?
|
| Immunodominant Epitopes | 1 | 2017 | 61 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2018 | 486 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2024 | 7226 | 0.040 |
Why?
|
| Adenoviruses, Human | 1 | 2017 | 181 | 0.040 |
Why?
|
| Herpesvirus 6, Human | 1 | 2017 | 81 | 0.040 |
Why?
|
| Middle Aged | 6 | 2022 | 86204 | 0.040 |
Why?
|
| Milk, Human | 1 | 2019 | 277 | 0.040 |
Why?
|
| HLA Antigens | 1 | 2019 | 546 | 0.040 |
Why?
|
| Rituximab | 1 | 2022 | 1528 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2018 | 441 | 0.030 |
Why?
|
| Neurons | 1 | 2007 | 2287 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 408 | 0.030 |
Why?
|
| Cytarabine | 1 | 2022 | 1973 | 0.030 |
Why?
|
| Sepsis | 1 | 2020 | 652 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2017 | 9180 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2017 | 974 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2014 | 249 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 493 | 0.030 |
Why?
|
| NADPH Oxidase 2 | 1 | 2013 | 47 | 0.030 |
Why?
|
| Siblings | 1 | 2015 | 285 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2017 | 1144 | 0.030 |
Why?
|
| North America | 1 | 2013 | 314 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 2803 | 0.030 |
Why?
|
| NADPH Oxidases | 1 | 2013 | 146 | 0.030 |
Why?
|
| Species Specificity | 1 | 2014 | 777 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 698 | 0.030 |
Why?
|
| Haplotypes | 1 | 2015 | 856 | 0.030 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2015 | 366 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 2352 | 0.030 |
Why?
|
| Th1 Cells | 1 | 2013 | 250 | 0.030 |
Why?
|
| Aspergillosis | 1 | 2014 | 246 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 2292 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 1538 | 0.030 |
Why?
|
| Osteogenesis | 1 | 2013 | 271 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 1217 | 0.020 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 305 | 0.020 |
Why?
|
| Risk | 1 | 2015 | 1972 | 0.020 |
Why?
|
| Texas | 1 | 2021 | 6311 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2014 | 1681 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 2265 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2015 | 1819 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 4314 | 0.020 |
Why?
|
| Animals | 4 | 2020 | 59536 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2013 | 1073 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2015 | 1146 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 1375 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2011 | 716 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 4892 | 0.020 |
Why?
|
| Kinetics | 1 | 2011 | 2049 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 2011 | 560 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2013 | 1459 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 5687 | 0.020 |
Why?
|
| Stem Cells | 1 | 2014 | 1213 | 0.020 |
Why?
|
| Mice | 3 | 2013 | 34495 | 0.020 |
Why?
|
| Aged | 2 | 2022 | 70117 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 945 | 0.020 |
Why?
|
| Cell Line | 1 | 2013 | 5114 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2008 | 694 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 6295 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 9244 | 0.020 |
Why?
|
| Pregnancy | 1 | 2017 | 7573 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2017 | 3341 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2013 | 5710 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 10035 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 5539 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 2403 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 6942 | 0.010 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2014 | 2979 | 0.010 |
Why?
|
| Time Factors | 1 | 2014 | 12926 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2008 | 4143 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 15862 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 4971 | 0.010 |
Why?
|
| Apoptosis | 1 | 2011 | 7591 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 7548 | 0.010 |
Why?
|